Selected article for: "co receptor and high mortality"
Author: Phyu Khin, Phyu; Cha, Seon-Heui; Jun, Hee-Sook; Han Lee, Jong
Title: A potential therapeutic combination for treatment of COVID-19: synergistic effect of DPP4 and RAAS suppression
  • Cord-id: ayf42grs
  • Document date: 2020_8_14
    • ID: ayf42grs
    Snippet: Abstract COVID-19, caused by the novel coronavirus SARS-CoV-2, is an abbreviated name for coronavirus disease 2019. COVID-19 became a global pandemic in early 2020. It predominantly affects not only the upper and lower respiratory tract, but also multiple organs, including the kidney, heart, and brain. The mortality of COVID-19 patients is high in men and in elderly patients with age-related diseases such as hypertension and diabetes. The angiotensin converting enzyme-2 (ACE-2), a component in t
    Document: Abstract COVID-19, caused by the novel coronavirus SARS-CoV-2, is an abbreviated name for coronavirus disease 2019. COVID-19 became a global pandemic in early 2020. It predominantly affects not only the upper and lower respiratory tract, but also multiple organs, including the kidney, heart, and brain. The mortality of COVID-19 patients is high in men and in elderly patients with age-related diseases such as hypertension and diabetes. The angiotensin converting enzyme-2 (ACE-2), a component in the renin–angiotensin–aldosterone system (RAAS), plays as cell surface receptors for SARS-CoV-2. A recent study proved that coronavirus SARS-CoV-2 also uses dipeptidyl peptidase-4 (DPP4, also known as adenosine deaminase complexing protein 2, CD26) as a co-receptor when entering cells. In addition, DPP4 is also implicated in the regulation of the immune response. Thus, the combination of DPP4 inhibition and suppression of ACE-2/RAAS may be a novel therapeutic strategy for combating this pandemic.

    Search related documents:
    Co phrase search for related documents
    • ace inhibitor and lung failure: 1
    • ace inhibitor and lung injury: 1, 2, 3, 4
    • acute respiratory distress syndrome and administer antiviral: 1
    • acute respiratory distress syndrome and low expression: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • acute respiratory distress syndrome and low expression level: 1
    • acute respiratory distress syndrome and lung failure: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory distress syndrome and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory distress syndrome and lung injury hypertension: 1
    • adenosine deaminase and low expression: 1
    • adenosine deaminase and low expression level: 1
    • adenosine deaminase and lung injury: 1, 2
    • low expression and lung failure: 1
    • low expression and lung injury: 1, 2, 3, 4